Unicycive Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share

Net Loss Per Share

12 Months Ended

Dec. 31, 2021

12. Net loss per share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

	Year Ended December 31, 2020			Year Ended December 31, 2021
Numerator:
Net loss	$	(2,264	)	$	(10,017	)

Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted		8,499,687			11,675,750
Net loss per share attributable to common stockholders, basic and diluted	$	(0.27	)	$	(0.86	)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	Year Ended December 31, 2020		Year Ended December 31, 2021

Options to purchase common stock		786,047		1,211,068
Warrants to purchase common stock		-		4,784,193
Total		786,047		5,995,261